Premature Rupture of Membranes With a Bishop Score<6: Comparison of Medical Induction/Expectant Management

Sponsor
Rambam Health Care Campus (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02825641
Collaborator
(none)
458
1
4
67.9
6.7

Study Details

Study Description

Brief Summary

The study is intended to compare expectant management and on presentation labor induction in women with premature rupture of membranes.

The means of labor induction and cervical ripening are either oxytocin or dinoprostone.

Expectant management in this obstetrical state means waiting 24 hours from the onset of rupture of membranes and then commencing labor induction with either oxytocin or dinoprostone depending on the patient's obstetrical history and cervical condition.

The investigators' hypothesis is that active management will lead to a higher rate of vaginal deliveries, a shorter interval between the time of rupture of membranes and the time of delivery, a lower rate of cesarean sections and a better obstetric result for the mother and the fetus/newborn.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

In the setting of premature rupture of membranes in term pregnancies, it is customary in women who are not in active labor to wait for 24 hours before attempting to induce labor. The means of labor induction used at our medical center are either intravenous oxytocin or per-vaginal dinoprostone, depending on patient's obstetric history and cervical conditions.

The investigators hypothesize that commencing induction of labor at presentation in these women by either means of induction will lead to higher rates of vaginal delivery, shorter intervals between the time of onset of rupture of membranes and the time of delivery and lower rates of cesarean sections.

The participants in the study, upon signing informed consents, will be randomized to 4 groups-2 groups of expectant management in which labor induction will be commenced after 24 hours with either oxytocin or dinoprostone and 2 groups of active management in which labor induction will be commenced at presentation with either oxytocin or dinoprostone.

The participants will be followed from the time of presentation with rupture of membranes at the delivery room and until the time of delivery.

Further obstetric, clinical and demographic information will be acquired from the patient's electronic medical file for analysis accuracy and sub-analysis.

Study Design

Study Type:
Interventional
Actual Enrollment :
458 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Premature Rupture of Membranes at Term With an Unfavorable Cervix (Bishop Score<6): Comparison of Oxytocin, Dinoprostone Induction and Expectant Management
Actual Study Start Date :
Aug 1, 2016
Actual Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Mar 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Expectant Management-Dinoprostone

Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6). Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions.

Drug: Dinoprostone
Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.

Active Comparator: Expectant Management-Oxytocin

Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6). Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions.

Drug: Oxytocin
Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.
Other Names:
  • Pitocin
  • Experimental: Active Management-Dinoprostone

    Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6). Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions.

    Drug: Dinoprostone
    Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.

    Experimental: Active Management-Oxytocin

    Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6). Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions.

    Drug: Oxytocin
    Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women: Induction of labor on presentation at the delivery room. Induction of labor after 24 hours of rupture of membranes.
    Other Names:
  • Pitocin
  • Outcome Measures

    Primary Outcome Measures

    1. The percentage of participants that achieved vaginal delivery [Up to 7 days from the time of presentation with rupture of membranes]

    Secondary Outcome Measures

    1. Interval from the time of onset of premature rupture of membranes and the time of delivery (In minutes) [Up to 7 days from the time of presentation with rupture of membranes]

    2. The percentage of participants that required caesarian delivery [Up to 7 days from the time of presentation with rupture of membranes]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Term pregnancies >37 weeks of gestation.

    • Certain rupture of membranes.

    • Bishop score < 6.

    • Singleton pregnancies.

    • Vertex presentation.

    • No obstetric or clinical contraindications for labor induction.

    • Reactive non stress test on presentation.

    Exclusion Criteria:
    • Previous cesarean section.

    • Previous uterine surgeries (Myomectomy etc.).

    • Placenta Previa.

    • Multiple gestation pregnancies.

    • Pregnancies with history of fetal reduction or Intrapartum uterine fetal demise.

    • Known fetal defects/Chromosomal abnormalities.

    • Active genital Herpes.

    • HIV carrier.

    • Contractions that are less than 10 minutes apart.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rambam health care campus Haifa Israel

    Sponsors and Collaborators

    • Rambam Health Care Campus

    Investigators

    • Principal Investigator: Amir Weissman, MD, Rambam Health Care Campus

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ROY LAUTERBACH MD, MD, Rambam Health Care Campus
    ClinicalTrials.gov Identifier:
    NCT02825641
    Other Study ID Numbers:
    • 0213-15-RMB
    First Posted:
    Jul 7, 2016
    Last Update Posted:
    Nov 18, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2021